Study record
MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model
Wu N, Shen C, Wang J et al. · Cardiovasc Drugs Ther · 2025
AnimalMOTS-c administeredEvidence tier C
What this study reported
Reported that administered MOTS-c was associated with less cardiac dysfunction, dilatation and adverse remodelling in mice with streptozotocin-induced type 1 diabetes, alongside restored AMPK signalling and lower inflammatory markers.
Limitations
Single chemically induced diabetes model in male mice; group sizes and blinding are not reported; continuous pump exposure is unlike physiological peptide levels.
Study record
| Study model | Animal study (in vivo) |
|---|---|
| Substance studied | MOTS-c administeredSynthetic MOTS-c was given to cells, animals or people. |
| Species | mouse |
| System studied | Male C57BL/6 mice with streptozotocin-induced type 1 diabetes and diabetic cardiomyopathy |
| Population | Not reported |
| Design | Controlled animal experiment |
| Sample size as reported | Not reported |
| Control group | diabetic mice not given MOTS-c |
| Route (data field only) | subcutaneous |
| Endpoints measured | cardiac function; cardiac histology; ventricular remodelling; AMPK signalling; myocardial inflammatory markers |
| Pathways measured | AMPK signalling · Inflammation |
| Research areas | Cardiovascular · Metabolic |
| Evidence tier | C — Animal in vivo |
| Publication types | Journal Article, Research Support, Non-U.S. Gov't |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- Mammalian
- Sample size
- Not reported
- Controls
- Appropriate
- Outcome validity
- Surrogate
- Support for its own conclusion
- Moderate
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.